csbj.com
Idenix tumbles on hepatitis drug safety concerns
Shares of Idenix Pharmaceuticals plunged Thursday after federal regulators halted trials of its hepatitis C drug due to the potential for heart damage. Two weeks, Bristol-Myers shut down a clinical trial of its hepatitis C treatment because a patient suffered heart failure during a clinical trial. The Food and Drug Administration has …